12. COMMITMENTS AND CONTINGENCIES We have a supply agreement with Fujifilm covering the commercial production of the recombinant antigen used in the manufacture of PROVENGE. On May 12, 2010, we entered into a Second Amendment to the supply agreement to extend the term of the agreement through December 31, 2018. Unless terminated, the agreement will renew automatically thereafter for additional 5 -year terms. The agreement may be terminated upon written notice by us or Fujifilm at least 24 months before the end of a renewal term or by either party in the event of an uncured material breach or default by the other party. We currently have commitments with Fujifilm to purchase antigen under three orders. We have a remaining obligation of approximately $ 2.3 million under the 2011 order, for which delivery commenced in the second quarter 2011. In addition, we have entered into commitments with Fujifilm to purchase antigen in 2012 for a total of $ 41.5 million and in 2013 for a total of $ 43.8 million. Payments on these commitments may begin in 2012 and will likely continue through 2014. The majority of our operating lease payments relate to two leases entered into in 2011 in Seattle, Washington, which collectively cover our principal corporate offices in Seattle, and the manufacturing facility leases in Morris Plains, New Jersey, Orange County, California and Atlanta, Georgia. In February 2011, we entered into a lease with Northwestern Mutual Life Insurance Company for office space of 179,656 square feet in Seattle, Washington. This lease was assigned to CommonWealth Partners in April 2012. The initial lease term is for five and a half years, with one renewal term of two and a half years. In June 2012, we amended the lease to reduce the premises to 158,081 square feet. The aggregate remaining rent payable for the amended lease agreement under the initial lease term is approximately $ 16.4 million. The lease required us to provide the landlord with a letter of credit as a security deposit. We provided the bank that is